A cancer stage can sound like a final verdict when you first see it in a scan report or hear it during an oncology consultation. In reality, ovarian cancer stages describe the extent of disease, not your prognosis, strength, or symptoms. They show where the cancer is found and how far it has spread.
Your first staging estimate may not be clear at the first appointment. Scans, blood tests, a biopsy, and sometimes surgery add important information, so the result can change. Knowing how the system works can help you ask focused questions and understand your diagnosis and treatment.
Key Takeaways
- Ovarian cancer stages use the FIGO system to describe where the cancer is found and how far it has spread; they do not measure symptoms, strength, or determine an individual prognosis.
- Stage I is limited to the ovary or fallopian tube, Stage II involves the pelvis, Stage III includes spread within the abdominal cavity or to retroperitoneal lymph nodes, and Stage IV means distant metastasis.
- Clinical staging from scans and tests may be refined by surgical findings and pathology, including tissue samples, lymph nodes, peritoneal washings, and residual disease after surgery.
- Treatment depends on more than stage, including cancer type, grade, biomarkers, genetic results, overall health, operability, fertility wishes, and personal treatment goals.
- CA-125 and imaging can support assessment and treatment monitoring, but neither can establish the stage alone. Ask your oncology team to explain the evidence behind your stage and how it affects your treatment options.
Ovarian cancer stages I to IV at a glance
Doctors usually use the International Federation of Gynecology and Obstetrics, or FIGO system, to classify ovarian cancer. The same framework applies to fallopian tube cancer and primary peritoneal cancer because these cancers can behave and spread similarly.
The four main stages are based on the location and extent of the cancer:
| Stage | Plain-language meaning |
|---|---|
| Stage I | Cancer is limited to one or both ovaries, or fallopian tubes. |
| Stage II | Cancer has spread within the pelvis, such as to the uterus or nearby pelvic tissues. |
| Stage III | Cancer has spread outside the pelvis within the peritoneal cavity, or to retroperitoneal lymph nodes. |
| Stage IV | Cancer has spread to distant sites outside the abdominal cavity, such as fluid around the lungs or organs outside the abdomen. |
The stages do not measure pain, symptoms, or how well someone feels. Someone with a smaller cancer may feel quite unwell, while another person with more extensive disease may have few symptoms. Persistent bloating, pelvic or abdominal pain, feeling full quickly, and changes in urinary habits still need medical assessment.
Stage I: cancer remains in the ovary or fallopian tube
Stage I means the cancer appears limited to the ovaries or fallopian tubes. It has not spread to nearby lymph nodes or distant organs.
- Stage IA affects one ovary or fallopian tube. The outer capsule remains intact, there is no cancer on the surface, and fluid samples show no malignant cells.
- Stage IB affects both ovaries or both fallopian tubes, while meeting the same capsule and fluid criteria.
- Stage IC includes cancer confined to one or both ovaries or tubes, but with factors that raise concern for cells entering the abdominal cavity, including a surgical spill.
FIGO divides Stage IC into three parts. IC1 refers to a surgical spill during the operation. IC2 means the capsule ruptured before surgery or cancer was found on the organ surface. IC3 means malignant cells were detected in ascites, which is fluid in the abdomen, or in peritoneal washings.
These details can affect how doctors interpret the diagnosis after surgery. The tumour family, including germ cell tumors, may matter even when the stage number is similar. Grade, complete pathology findings, fertility wishes, and general health also matter.
Stage II: spread within the pelvis
Stage II ovarian cancer means pelvic extension beyond the ovary, while remaining within the pelvis. It may involve the uterus, the opposite fallopian tube, or other pelvic tissues.
Stage IIA includes extension to the uterus or fallopian tubes. Stage IIB means cancer has reached other tissues inside the pelvis. This distinction reflects the pattern of pelvic extension. Although Stage II disease has moved beyond the ovary, it has not spread above the pelvis or to distant sites.
Stage III: peritoneal spread or lymph node involvement
Stage III is common in epithelial ovarian cancer. It means cancer has spread outside the pelvis within the peritoneal cavity, or doctors have found cancer in retroperitoneal lymph nodes. This pattern of lymph node metastasis involves nodes behind the abdominal organs, including pelvic and para-aortic nodes.
Ovarian cancer cells can travel through abdominal fluid and settle on the thin lining of the abdomen, called the peritoneum. This spread is known as peritoneal dissemination.
Extensive peritoneal deposits are sometimes called peritoneal carcinomatosis. Such peritoneal carcinomatosis may involve the omentum, bowel surfaces, diaphragm, or the outer surface of the liver or spleen.
Stage III has several subgroups:
- Stage IIIA1 means cancer is found only in lymph nodes within the retroperitoneum. It is further divided by whether deposits measure 10 mm or less, or more than 10 mm.
- Stage IIIA2 means there is microscopic cancer outside the pelvis. Doctors can see it only under a microscope.
- Stage IIIB means visible peritoneal deposits outside the pelvis are 2 cm or smaller.
- Stage IIIC means visible deposits outside the pelvis are larger than 2 cm.
Peritoneal deposits on the surface of the liver or spleen are usually Stage III disease. Cancer inside the liver or spleen tissue is Stage IVB, because it involves the organ rather than its surface.
Stage IV: distant metastasis
Stage IV means ovarian cancer has spread beyond the peritoneal cavity, indicating distant metastasis. It does not simply mean there is extensive disease in the abdomen.
Stage IVA refers to a pleural effusion, or fluid around the lungs, when laboratory testing confirms malignant cells. Stage IVB includes cancer inside organs such as the liver, spread to organs outside the abdomen, or cancer in lymph nodes outside the abdominal cavity, including inguinal lymph nodes.
The distinction matters because peritoneal cancer within the abdomen is Stage III, even when widespread. Stage IV requires evidence of spread to a distant site. The stage at diagnosis is not the same as the amount of residual disease after surgery. Your oncologist can explain what a scan finding means in your own case.
How FIGO and TNM classify ovarian cancer
The FIGO system is the main language used by gynaecological cancer teams worldwide. The American Joint Committee on Cancer, or AJCC, also uses the TNM staging system. In practice, the framework and TNM align closely across these related cancers.
The American Cancer Society’s ovarian cancer staging guide explains the three TNM components:
- T, or tumour, describes the primary cancer and whether it has grown beyond the ovary or fallopian tube.
- N, or nodes, describes spread to regional lymph nodes.
- M, or metastasis, indicates distant metastasis.
In broad terms, this stage grouping maps Stage I to T1 N0 M0, while Stage II maps to T2 N0 M0. Stage III includes cancer outside the pelvis and/or regional nodal disease without spread to distant sites. Stage IV means M1, indicating spread to distant sites.
The framework was revised in 2014 to clarify several important areas, including Stage IC and Stage IIIA1. The published FIGO staging update confirms that the same classification covers cancers starting in the ovary, fallopian tube, and peritoneum.
Histological type still matters. Epithelial ovarian cancer and germ cell tumors may need different pathology-specific treatment interpretation, so the framework does not determine treatment by itself. Neither TNM nor the framework should replace documentation of postoperative residual disease.
Primary peritoneal cancer starts in the lining of the abdomen rather than an ovary. Fallopian tube cancer begins in a fallopian tube. Your pathology report may name one of these origins, yet the staging and ovarian cancer treatment approach can be similar.
Clinical stage and pathological stage are not the same
You may hear your doctor use the terms clinical assessment and pathology findings. Both are useful, but they rely on different evidence.
Clinical assessment is the best estimate before major treatment begins. It draws on your symptoms, examination, CT scans, MRI scans, blood tests, chest imaging, and biopsy results. This estimate helps your team decide whether primary debulking surgery is suitable or neoadjuvant chemotherapy should come first.
Pathology findings come from tissue and samples collected during surgery, including the removed tumour, biopsies, lymph nodes, omentum, and peritoneal washings. A pathologist examines them under a microscope, which can confirm or refine the clinical assessment.
For apparent early-stage disease, staging surgery may inspect the entire abdominal cavity, collect washings, and sample selected tissues. It may assess lymph nodes for lymph node metastasis and document pelvic extension, visible residual disease, or surgical spill. The operation plan differs for each person, and fertility-sparing surgery may be considered in carefully selected situations.
A pathology report review can be useful when the diagnosis is uncommon, the cancer’s origin is uncertain, or peritoneal carcinomatosis is difficult to interpret. It may clarify microscopic findings and how they relate to residual disease documented during surgery. You can also request copies of your biopsy result, operation note, scan reports, and laboratory results.
The CA-125 blood test is often used to support ovarian cancer assessment and monitor treatment response. However, it cannot establish stage by itself. Some non-cancer conditions can also raise CA-125, while some ovarian cancers produce little of it.
For technical reference, Johns Hopkins Pathology’s staging summary outlines how tumour extent, lymph nodes, and distant metastasis map to FIGO stages.
What scans can and cannot show before surgery
A contrast CT scan of the chest, abdomen, and pelvis is often central to pre-treatment cancer staging. It assesses the lungs, liver surface, peritoneal cavity, and lymph nodes. It can show ascites, omental thickening, peritoneal nodules, bowel involvement, pleural effusion, and signs that may suggest peritoneal carcinomatosis.
MRI can give a clearer picture of a pelvic mass and nearby structures. A PET scan for cancer may help in selected situations, such as uncertain scan findings or suspected recurrence. Scan findings and diagnostic laparoscopy may help determine whether neoadjuvant chemotherapy should precede surgery. Imaging is not a replacement for pathology.
Radiologists also assess whether cancer can likely be removed safely. They look at where deposits sit, how widely peritoneal carcinomatosis is distributed, and whether disease affects areas that make complete surgery difficult. Some surgical teams use a peritoneal cancer index (PCI) to describe the amount and distribution of disease, helping estimate possible residual disease after surgery.
Imaging cannot detect every tiny cancer deposit from peritoneal dissemination. A CT scan that looks reassuring does not always rule out microscopic residual disease. Likewise, an alarming scan may need confirmation during surgery or through a biopsy.
A detailed ovarian tumour staging reference can help you recognise terms in a pathology report, but your own medical team must interpret those terms alongside your scans and health history.
How the stage guides ovarian cancer treatment
Stage is only one factor in a treatment plan. For epithelial ovarian cancer, histological type, grade, biomarkers, genetic results, age, health, operability, treatment availability, and patient goals all matter.
For many Stage I cancers, surgery is the main treatment. Chemotherapy may be discussed when pathology shows a higher-risk subtype, such as high grade serous ovarian cancer, a higher grade, or Stage IC features. Some non-epithelial cancers, including germ cell tumors, may need different systemic treatment.
For Stage II, III, and IV disease, treatment often combines surgery with platinum-based chemotherapy. If surgery comes first, primary debulking surgery aims to remove visible cancer as safely as possible. Spread through the peritoneal cavity, including peritoneal carcinomatosis, can affect surgical extent and residual disease after primary surgery. The operative report records residual disease and assesses whether optimal cytoreduction was achieved.
Sometimes scans, diagnostic laparoscopy, or overall health suggest extensive surgery should not come first. The team may recommend a biopsy followed by neoadjuvant chemotherapy. If the cancer responds, interval debulking surgery may become appropriate. This operation follows neoadjuvant chemotherapy and may leave residual disease.
Maintenance targeted therapy may be considered after initial treatment when genetic or biomarker testing suggests benefit. Options can include PARP inhibitors or bevacizumab in appropriate circumstances, but these medicines aren’t suitable for every ovarian cancer type or patient. Follow-up or further treatment discussions may also consider residual disease, treatment response, and overall health.
Radiotherapy is not usually the main treatment for this cancer, but it may control a specific symptom or tumour area in selected circumstances. When disease is difficult to remove, including some cases of peritoneal carcinomatosis, HIPEC may be considered in selected surgical settings. Suitability depends on the disease pattern, operation plan, and specialist assessment.
The TNM and FIGO classification overview offers more detail, but it cannot replace a discussion about your pathology and treatment goals. Population survival rates cannot predict an individual patient’s outcome.
Treatment expenses can vary widely between public and private care, and between hospitals in Malaysia. Ask for a written cancer treatment quotation where possible. It can help you understand professional fees, surgery, chemotherapy medicines, scans, hospital stays, genetic testing, and supportive medicines.
Preparing for an oncology consultation or second opinion
Bring a family member or trusted friend to an oncology consultation if you can. They can take notes, help you remember questions, and support you when information feels overwhelming.
Useful questions to ask an oncologist include:
- What is my confirmed stage, and what evidence supports it?
- What type and grade of ovarian cancer do I have?
- Has the pathology been reviewed by a gynaecological cancer specialist?
- Is primary debulking surgery appropriate first, or would neoadjuvant chemotherapy be safer?
- If surgery is recommended, how much residual disease might remain, and how would that affect the next steps?
- What is the aim of treatment in my situation?
- Should I have genetic testing for cancer or biomarker testing?
- What side effects, costs, waiting times, and practical support should I expect?
A cancer second opinion is not a rejection of your current doctor. It may confirm the existing diagnosis and plan, clarify a difficult staging issue, recommend more testing, or identify another medically appropriate approach. Some people seek an oncology second opinion when surgery may be extensive, especially if scans suggest peritoneal carcinomatosis. Others seek one when the diagnosis is rare, scan findings are unclear, or treatment choices feel difficult to weigh.
If you need help organising reports for review, Explore Medical Report Review Support for coordination help with medical information. It does not provide diagnosis or interpret reports in place of your treating specialist.
You may also Explore Cancer Second Opinion Support when considering coordination for another qualified specialist perspective. A review of the proposed care may confirm that your present plan remains the most appropriate one.
Different cancer hospitals can have different specialist teams, operating experience, and access to testing. They may also vary in their experience managing peritoneal carcinomatosis, costs, waiting times, and supportive-care services. If you are considering care outside Malaysia, Explore Overseas Hospital Options for medical-travel and hospital-enquiry coordination. Overseas cancer treatment does not automatically provide a better outcome, so discuss any move with your oncologist first.
For a clearer overview of evidence-based cancer treatment options and possible care pathways, Explore Cancer Treatment Options. Complementary therapies such as counselling, nutrition support, gentle movement, and symptom management may support wellbeing. They do not replace surgery, chemotherapy, or other prescribed oncology care.
Frequently Asked Questions
What do ovarian cancer stages mean?
Ovarian cancer stages describe the location and extent of the cancer, from Stage I limited to the ovary or fallopian tube to Stage IV with distant spread. The stage does not measure how unwell someone feels or predict one person’s outcome by itself.
Can the ovarian cancer stage change after surgery?
Yes. The initial clinical stage is based on examinations, scans, blood tests, and biopsy findings, while surgery and pathology may provide more detailed information. These findings can confirm or refine the original staging estimate.
Can a CA-125 blood test determine the stage?
No. CA-125 may support assessment and help monitor response to treatment, but it cannot establish the stage on its own. Some non-cancer conditions can raise CA-125, and some ovarian cancers produce little of it.
What is the difference between Stage III and Stage IV ovarian cancer?
Stage III generally means the cancer has spread outside the pelvis within the peritoneal cavity or to retroperitoneal lymph nodes. Stage IV requires evidence of distant metastasis, such as malignant cells in fluid around the lungs or cancer inside a distant organ.
How does the stage affect ovarian cancer treatment?
Stage helps guide decisions about surgery, chemotherapy, and possible maintenance treatment, but it is not the only factor. Cancer type, grade, biomarkers, genetic findings, overall health, operability, residual disease, and treatment goals also influence the recommended plan.
Clear staging supports better questions
Understanding ovarian cancer stages helps you make sense of a medical report. The stage is one part of decision-making. Residual disease after surgery may also affect treatment planning. Your cancer type, pathology, scans, genetic findings, health, and treatment priorities all shape the plan your team recommends.
Keep copies of your records, ask for plain-language explanations, and take time to discuss major decisions with qualified professionals. Clear information can help you and your family take part in each step with greater confidence.
Medical disclaimer: This content is for general educational information only. It may not apply to every patient and should not be treated as medical advice, a diagnosis, or a treatment recommendation. Consult your own doctor, oncologist, or qualified healthcare professional before making medical decisions.
